Intelligence · Clinical Development
Pipeline search results
Programs matching “omid” across our ClinicalTrials.gov index — phase, modality, sponsor, and trial IDs.
Quick answer
Showing 143 pipeline programs matching "omid" from NovaPharmaNews Clinical Development Intelligence — phase, modality, sponsor, and ClinicalTrials.gov trial IDs.
Refine search
Search results
-
Romidepsin
Takeda
Lymphoma, T-Cell, Peripheral
1 trial -
Sublingual film containing Dexmedetomidine
BioXcel Therapeutics
Agitation,Psychomotor
1 trial -
TEMOZOLOMIDE
The George Institute
Diffuse low-grade gliomas
1 trial -
TEMOZOLOMIDE
Istituto Gentili S.r.l.
Patients with well differentiated neuroendocrine neoplasia (NENs) not eligible for active antitumoral treatments due to their clinical conditions.
1 trial -
TEMOZOLOMIDE , IRINOTECAN
Fondazione Telethon ETS
Stage II (pT4)/III colorectal cancer with positive circulating tumor DNA (ctDNA) after oxaliplatin-based adjuvant chemotherapy
1 trial -
TEMOZOLOMIDE for locally advanced rectal cancer (LARC)
Fondazione Telethon ETS
locally advanced rectal cancer (LARC)
1 trial -
Temozolomide
PUMA BIOTECHNOLOGY, INC.
Glioblastoma
1 trial -
Temozolomide
The First People's Hospital of Lianyungang
Cytokine-Induced Killer Cells
1 trial -
Teriflunomide
Xiyuan Hospital of China Academy of Chinese Medical Sciences
Immune Thrombocytopenia
2 trials -
Thalidomide and methotrexate
Xiyuan Hospital of China Academy of Chinese Medical Sciences
T-LGL Leukemia
1 trial -
Zanubrutinib+Rituximab+Lenalidomide
The First People's Hospital of Lianyungang
Diffuse Large B Cell Lymphoma
1 trial -
aminomidazole carboxamide riboside
Ultragenyx UK Limited
Lesch-Nyhan Syndrome
1 trial -
cemsidomide
C4 Therapeutics
Multiple Myeloma
2 trials -
lenalidomide combined with rituximab
The First People's Hospital of Lianyungang
Diffuse Large B Cell Lymphoma
1 trial -
placebo
The First People's Hospital of Lianyungang
COVID-19 Thalidomide
1 trial -
silevertinib in combination with temozolomide
Blackmores Limited
Glioblastoma (GBM)
1 trial -
temozolomide
Children's Hospital of Fudan University
Brain and Central Nervous System Tumors
1 trial -
temozolomide
Universal Integrated
Cancer
1 trial -
thalidomide
Ultragenyx UK Limited
HIV Infections
1 trial -
tiotropium-bromide
Boehringer Ingelheim
Asthma
1 trial -
Cemsidomide
C4 Therapeutics
Multiple Myeloma (MM)
1 trial -
Dexmedetomidine
The First People's Hospital of Lianyungang
Heart Injuries
1 trial -
Dexmedetomidine
The First People's Hospital of Lianyungang
Cesarean Section, Affecting Fetus or Newborn
1 trial -
Dexmedetomidine (DEX) for sublingual (SL) administration (BXCL501) - 40µg
BioXcel Therapeutics
Alcohol Use Disorder (AUD)
1 trial
Frequently asked questions
What is the Clinical Development Intelligence Platform?
It is NovaPharmaNews pipeline intelligence hub covering 20,548 clinical development programs — not just a directory. It includes phase distribution dashboards, therapeutic area overviews, NDA/BLA watchlists, upcoming readouts, company pipeline rankings, competitive landscape maps, and personalized watchlists.
How does this compare to Evaluate Pharma or Citeline?
Like Evaluate Pharma and Citeline Trialtrove, we index ClinicalTrials.gov programs by sponsor, phase, and indication. Our platform adds cross-links to NovaPharmaNews company profiles, drug INN pages, patents, and congress readout calendars — improving crawl depth and reducing orphan program pages.
Where does pipeline data come from?
Program records derive from ClinicalTrials.gov and link to sponsor company profiles. Trial status and phase reflect registry data at last sync — verify on ClinicalTrials.gov before investment decisions. See our data sources page for attribution.
Can I follow a company or program for updates?
Yes — use the watchlist forms on this page to follow sponsors, individual programs, disease clusters, or therapeutic areas. Alerts use the same subscription infrastructure as our events intelligence hub.